Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma

Background: Combinations of alkylating agents with proteasome inhibitors have demonstrated efficacy in newly diagnosed and relapsed multiple myeloma (MM), with melphalan or cyclophosphamide combinations being some of the commonly used regimens for initial treatment of MM. Ixazomib (Ixa) is an oral p...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2019-11, Vol.134 (Supplement_1), p.1904-1904
Hauptverfasser:	Buadi, Francis K., Lacy, Martha Q., Laplant, Betsy, Wolfe, Eric, Gertz, Morie A., Ailawadhi, Sikander, Hayman, Suzanne R., Go, Ronald S., Helgeson, Dania Kaehlyn, Roy, Vivek, Reeder, Craig B., Fonder, Amie, Hwa, Yi L., Hobbs, Miriam A., Bergsagel, P. Leif, Fonseca, Rafael, Dingli, David, Gonsalves, Wilson I, Kapoor, Prashant, Chanan-Khan, Asher A., Kourelis, Taxiarchis, Larsen, Jeremy, Russell, Stephen J, Lust, John A., Sher, Taimur, Siddiqui, Mustaqeem A., Stewart, A. Keith, Warsame, Rahma M, Rajkumar, S. Vincent, Kyle, Robert A., Kumar, Shaji K.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!